

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
60726-AZU.S. Serial No.  
10/776,442INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)Applicant:  
Moses Rodriguez and Daren UreFiling Date:  
February 10, 2004Group Art Unit  
1614

## U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
CYW	1	4 1 2 9 6 6 6	12/12/78	Wizerkaniuk;			
	2	4 5 9 4 4 0 9	6/10/86	Hayashi et al.;			
	3	5 9 6 5 6 0 0	10/12/99	Sato et al.;			
	4	6 0 2 4 9 8 1	2/15/00	Khankari et al.;			
	5	6 1 6 2 8 0 0	12/19/00	Dolle et al.;			
	6	6 5 1 4 9 3 8	2/4/03	Gad et al.;			
	7	6 6 2 0 8 4 7	9/16/03	Konfino et al.;			
	8	6 8 0 0 2 8 5	10/5/04	Rodriguez et al.;			
	9	6 8 0 0 2 8 7	10/5/04	Gad et al.;			
	10	6 8 4 4 3 1 4	1/18/05	Eisenbach-Schwartz et al.;			
	11	6 9 3 9 5 3 9	9/6/05	Konfino et al.;			
CYW	12	7 0 2 2 6 6 3	4/4/06	Gilbert et al.;			

		Document Number	Date	Country	Class	Subclass	Translation
							Yes No
CYW	37	0 3 7 8 2 4 6	6/18/86	Europe;			
CYW	38	3 9 3 0 7 3 3	3/28/91	Germany;			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CYW	48	Aharoni, et al., "Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis", <u>Proc. Natl. Acad. Sci. USA</u> , 1997, <u>94</u> , 10821-10826;
	49	Aharoni, et al., "Cop 1 Specific Suppressor Cells Inhibit Experimental Allergic Encephalomyelitis Induced by Either Mouse Spinal Cord Homogenate or Proteolipid Protein Peptide 139-151", <u>Neurology</u> , 1997, Vol. 48, No. 3, A422 (Abstract);
	50	Aharoni, et al., "Bystander Suppression of Experimental Autoimmune Encephalomyelitis by T Cell Lines and Clones of the Th2 Type Induced by Copolymer 1", <u>J. Neuroimmunol.</u> , 1998, <u>91</u> (1-2), 135-146;
	51	Bodanszky, M., "Principles of Peptide Synthesis", Springer-Verlag, Berlin, Heidelberg, New York, Tokyo, 1984, pp. 118-229;
	52	Bornstein, et al., "Rationale For Immunomodulating Therapies of Multiple Sclerosis: Clinical Trial Design In Multiple Sclerosis Therapy", <u>Neurol.</u> , 1988, Vol. 38 (Suppl.2), pp. 80-81;
	53	Bornstein, M., "Clinical Experience: Hopeful Prospects In Multiple Sclerosis", <u>Hospital Practice</u> , 1992, Vol. 27, No. 5, pp. 135-158;
	54	Cazzato, et al., "Treatment of Multiple Sclerosis. The Present and the Future. Study Group on Diagnosis and Therapy of Multiple Sclerosis", Database Medline on STN, Instituto do Clinica Neurologica, Universit'a, Trieste, Italy: Medline AN: 2000060325, Recent Progressi in Medicina. October 1999, <u>90</u> (10), 538-544
	55	Duda, et al., "Human and Murine CD4 T Cell Reactivity to a Complex Antigen: Recognition of the Synthetic Random Polypeptide Glatiramer Acetate", <u>The Journal of Immunology</u> , 2000, <u>165</u> , 7300-7307;
	56	Gurevich, "Study of the MHC-competition Between BP and Cop 1 Using Human Cytotoxic T-cell Clones", <u>Israel J. Med. Sci.</u> , 1993 (Abstract);
CYW	57	Johnson, et al. "Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group", <u>Neurology</u> , 45(7), 1268 (Abstract);

EXAMINER /Chang-Yu Wang/ DATE CONSIDERED 10/04/2006

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Inventors: Moses Rodriguez and Daren Ure  
Serial No.: 10/776,442  
Filed: February 10, 2004  
Exhibit A

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60726-AZ		U.S. Serial No. 10/776,442									
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)					<b>Applicant:</b> Moses Rodriguez and Daren Ure											
					<b>Filing Date:</b> February 10, 2004		<b>Group Art Unit</b> 1614									
<b>U.S. PATENT DOCUMENTS</b>																
Examiner Initial		Document Number							Date	Name	Class	Subclass	Filing Date if Appropriate			
	CYW	13	7	0	3	3	5	8	2	4/25/06	Yong, et al.;					
		14	7	0	7	4	5	8	0	7/22/06	Gad et al.;					
		15	20	02	00	37	8	4	8	3/28/02	Eisenbach-Schwartz et al.;					
		16	20	02	01	15	1	0	3	8/22/02	Gad et al.;					
		17	20	02	01	07	3	8	8	8/8/02	Vandenbark;					
		18	20	02	00	77	2	7	8	6/20/02	Yong et al.;					
		19	20	03	01	70	7	2	9	9/11/03	Klinger;					
		20	20	04	00	06	0	2	2	1/8/04	Strominger et al.;					
		21	20	04	01	06	5	5	4	6/3/04	Konfino et al.;					
		22	20	05	00	14	6	9	4	1/20/05	Yong et al.;					
		23	20	05	00	19	3	2	2	1/27/05	Rodriguez et al.;					
	CYW	24	20	05	00	38	2	3	3	2/17/05	Gad et al.;					
	<b>FOREIGN PATENT DOCUMENTS</b>															
			Document Number							Date	Country	Class	Subclass	Translation		
															Yes	No
	CYW	39	0	2	5	4	4	9	6	8/27/96	New Zealand;					
	CYW	40	0	3	3	6	6	9	0	1/12/98	New Zealand;					
	<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>															
	CYW	58	Korczyn, et al., "Safety profile of copolymer 1: analysis of cumulative experience in the United States and Israel", <u>J. Neurol.</u> , 1996, Vol. 243 (Suppl. 1): S23-S26;													
	59	Lovell, K. and Jones, M., "CNS Infections, Spongiform Encephalopathy and Demyelinating Diseases", Karol Marcinkowski U. Med. Sci., Dept. Pathol., Poland, last updated on 2003-04-20, URL: <a href="http://ampat.amu.edu.pl/guzyuno/CNS_INFE.HTM">http://ampat.amu.edu.pl/guzyuno/CNS_INFE.HTM</a> ;														
	60	Merck Manual of Diagnosis and Therapy, <u>Merck Research Laboratories</u> , Whitehouse Section, N.J., 17 <sup>th</sup> Ed., 1999, pp. 1300-1303, pp. 1312-1317;														
	61	Pharmacia Biotech Directory, 1996, pp. 340-341;														
	62	Physician's Desk Reference, 2000, Medical Economics Co. Inc., Montvale, NJ, 3115;														
	63	Rothbard, et al., "Interactions Between Immunogenic Peptides and MHC Proteins", <u>Annu. Rev. Immunol.</u> , 1991, 9, 527-565;														
	64	Salvetti, et al., "Myelin Basic Protein T Cell Epitopes in Patients with Multiple Sclerosis", <u>Department of Neurological Sciences, University of Rome, La Sapienza</u> 1991, 72 (Abstract);														
	65	Sela, et al., "Synthetic Approaches To Vaccines For Infectious And Autoimmune Diseases", <u>Vaccine</u> , 1992, Vol. 10, No. 14, pp. 991-999;														
CYW	66	Stark, "Expanded Clinical Trials of Treatments for Multiple Sclerosis (MS): Copolymer 1 (COP-1) Treatment Investigational New Drug (IND) Program", <u>Ann. Neurol.</u> , 1994, 36, 114-115														
EXAMINER		/Chang-Yu Wang/							DATE CONSIDERED		10/04/2006					

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60726-AZ		U.S. Serial No. 10/776,442								
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)					<b>Applicant:</b> Moses Rodriguez and Daren Ure										
					<b>Filing Date:</b> February 10, 2004		<b>Group Art Unit</b> 1614								
<b>U.S. PATENT DOCUMENTS</b>															
Examiner Initial		Document Number								Date	Name	Class	Subclass	Filing Date if Appropriate	
↓	CYW	25	20	05	01	70	0	0	4	8/4/05	Rosenberger et al.;				
		26	20	05	01	71	2	8	6	8/4/05	Konfino et al.;				
		27	20	05	02	56	0	4	6	11/17/05	Gad et al.;				
		28	20	06	00	52	5	8	6	3/9/06	Dolitzky;				
		29	20	06	01	22	1	1	3	6/8/06	Pinchasi et al.;				
		30	09	8	8	5	2	2	7	6/20/01	Rodriguez and Ure;				
		31	10	5	4	7	4	6	3	8/30/05	Pinchasi et al.;				
		32	10	5	5	6	4	5	4	11/17/05	Vollmer;				
		33	10	5	7	7	5	8	8	4/27/06	Rosenberger et al.;				
		34	11	2	2	8	8	5	0	9/14/05	Schwartz et al.;				
	35	11	3	3	6	2	5	1	1/20/06	Dolitzky;					
CYW	36	11	3	7	3	7	9	4	3/9/06	Pinchasi;					
<b>FOREIGN PATENT DOCUMENTS</b>															
		Document Number								Date	Country	Class	Subclass	Translation	
														Yes	No
↓	CYW	41	1	6	9	0	3	6	8	8/20/95	Russia;				
		42	1	4	6	9	8	2	6	11/20/95	Russia;				
		43	0	9	8	0	2	1	4	9/29/99	South Africa;				
		44	1	1	8	2	0	5	1	9/30/85	Soviet Union;				
		45	1	6	6	4	8	4	5	7/23/91	Soviet Union;				
		46	03	0	4	8	7	3	5	6/12/03	WO;				
CYW	47	06	0	5	0	1	2	2	5/11/06	WO;					
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>															
CYW	67	Teva, et al., "Copolymer-1 Glatiramer Acetate Copaxone Agent for Multiple Sclerosis", <u>Drugs of the Future</u> , 1998, Vol. 23, No. 2, pp. 213-214;													
CYW	68	Webb, et al., "Suppression of Experimental Allergic Encephalomyelitis in Rhesus Monkeys by a Synthetic Basic Copolymer", <u>Isr. J. Med. Sci.</u> , 1975, <u>11</u> , 1388 (Abstract);													
CYW	69	Wiesemann, et al., "Glatiramer Acetate (GA) induces IL-13/IL-5 secretion in naïve T cells", <u>Journal of Neuroimmunology</u> , 2001, 119, 137-144;													
EXAMINER /Chang-Yu Wang/		DATE CONSIDERED      10/04/2006													
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.															